SA516371613B1 - Cgrp صيغة قرص لمركبات نشطة تجاه - Google Patents
Cgrp صيغة قرص لمركبات نشطة تجاهInfo
- Publication number
- SA516371613B1 SA516371613B1 SA516371613A SA516371613A SA516371613B1 SA 516371613 B1 SA516371613 B1 SA 516371613B1 SA 516371613 A SA516371613 A SA 516371613A SA 516371613 A SA516371613 A SA 516371613A SA 516371613 B1 SA516371613 B1 SA 516371613B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- cgrp
- active compounds
- tablet formulation
- api
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000007916 tablet composition Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936019P | 2014-02-05 | 2014-02-05 | |
| US201462087366P | 2014-12-04 | 2014-12-04 | |
| PCT/US2015/013672 WO2015119848A1 (en) | 2014-02-05 | 2015-01-30 | Tablet formulation for cgrp-active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA516371613B1 true SA516371613B1 (ar) | 2021-06-19 |
Family
ID=53778348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA516371613A SA516371613B1 (ar) | 2014-02-05 | 2016-08-04 | Cgrp صيغة قرص لمركبات نشطة تجاه |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10117836B2 (enExample) |
| EP (1) | EP3102564A4 (enExample) |
| JP (2) | JP6491669B2 (enExample) |
| KR (3) | KR20220136460A (enExample) |
| CN (2) | CN112022818A (enExample) |
| AU (5) | AU2015214502B2 (enExample) |
| CA (1) | CA2937315A1 (enExample) |
| HK (1) | HK1232218A1 (enExample) |
| IL (1) | IL246828B (enExample) |
| MX (2) | MX383378B (enExample) |
| RU (2) | RU2019123406A (enExample) |
| SA (1) | SA516371613B1 (enExample) |
| WO (1) | WO2015119848A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI522355B (zh) * | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
| IL301979B2 (en) * | 2017-03-30 | 2024-05-01 | Merck Patent Gmbh | Spray dried solid dispersions comprising (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation |
| JP2021519288A (ja) * | 2018-03-25 | 2021-08-10 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | Ｃｇｒｐ関連障害のためのリメゲパント |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| RU2755571C1 (ru) * | 2020-06-09 | 2021-09-17 | Сергей Геннадьевич Каплунов | Способ изготовления гравюры на металле |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| IL302948A (en) * | 2020-11-19 | 2023-07-01 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3206675A1 (en) * | 2021-02-02 | 2022-08-11 | Markus Von Raumer | A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| AU2004222378B2 (en) | 2003-03-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin CGRP receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| ATE464305T1 (de) | 2004-09-13 | 2010-04-15 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| CA2599925A1 (en) | 2005-03-14 | 2006-09-21 | Merck & Co., Inc. | Cgrp receptor antagonists |
| AU2007212197B2 (en) * | 2006-02-09 | 2012-12-13 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
| BRPI0711352A2 (pt) | 2006-05-09 | 2011-09-27 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular |
| EP2161996B1 (en) | 2007-06-05 | 2014-07-16 | Merck Sharp & Dohme Corp. | Heterocyclic carboxamide cgrp receptor antagonists |
| US8450327B2 (en) | 2007-10-18 | 2013-05-28 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
| WO2009065922A2 (de) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
| WO2009100090A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| CN104983701A (zh) | 2008-04-15 | 2015-10-21 | 默沙东公司 | 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 |
| DK3222277T3 (da) * | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| US8765763B2 (en) | 2009-06-05 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Substituted piperazines as CGRP antagonists |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012064911A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012087777A1 (en) | 2010-12-22 | 2012-06-28 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide cgrp receptor antagonists |
| US9067941B2 (en) | 2010-12-22 | 2015-06-30 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide CGRP receptor antagonists |
| EP2654726A1 (en) * | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| US9109209B2 (en) | 2011-09-08 | 2015-08-18 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| DK2765990T3 (da) | 2011-10-14 | 2017-11-13 | Array Biopharma Inc | Faststofdispersion |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| AU2013232191B2 (en) | 2012-03-14 | 2017-03-30 | Merck Sharp & Dohme Llc | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| CN104411295B (zh) | 2012-04-25 | 2017-10-10 | 伊诺威斯药物公司 | 敏感化组合物和使用方法 |
| US9227973B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| WO2013169574A2 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| RU2690006C2 (ru) | 2013-09-16 | 2019-05-30 | Мерк Шарп И Доум Корп. | Композиции антагонистов рецепторов cgrp |
| US20160346198A1 (en) | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| EP3110427A4 (en) | 2014-02-24 | 2018-05-30 | Urigen Pharmaceuticals, Inc. | Compositions of pentosan polysulfate salts for oral administration and methods of use |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
| EA201890578A1 (ru) | 2015-09-24 | 2018-12-28 | Тева Фармасьютикалз Интернэшнл Гмбх | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| CN110621343A (zh) | 2017-03-02 | 2019-12-27 | 贝丝以色列女执事医疗中心 | 选择对针对降钙素基因相关肽的抗体有反应的头痛患者 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| CA3133912A1 (en) | 2019-04-18 | 2020-10-22 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| AU2020355233A1 (en) | 2019-09-25 | 2022-05-19 | Allergan Pharmaceuticals International Limited | Combination therapy with CGRP antagonists |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
-
2015
- 2015-01-30 EP EP15746768.9A patent/EP3102564A4/en active Pending
- 2015-01-30 AU AU2015214502A patent/AU2015214502B2/en active Active
- 2015-01-30 RU RU2019123406A patent/RU2019123406A/ru unknown
- 2015-01-30 JP JP2016548023A patent/JP6491669B2/ja active Active
- 2015-01-30 CN CN202010812438.5A patent/CN112022818A/zh active Pending
- 2015-01-30 KR KR1020227032939A patent/KR20220136460A/ko not_active Ceased
- 2015-01-30 HK HK17105813.5A patent/HK1232218A1/zh unknown
- 2015-01-30 WO PCT/US2015/013672 patent/WO2015119848A1/en not_active Ceased
- 2015-01-30 CN CN201580006288.6A patent/CN105960397B/zh active Active
- 2015-01-30 KR KR1020167024025A patent/KR102448369B1/ko active Active
- 2015-01-30 CA CA2937315A patent/CA2937315A1/en active Pending
- 2015-01-30 MX MX2016010169A patent/MX383378B/es unknown
- 2015-01-30 US US15/115,026 patent/US10117836B2/en active Active
- 2015-01-30 KR KR1020237022803A patent/KR20230107902A/ko not_active Ceased
- 2015-01-30 RU RU2016135536A patent/RU2696578C1/ru active
-
2016
- 2016-07-18 IL IL246828A patent/IL246828B/en active IP Right Grant
- 2016-08-04 SA SA516371613A patent/SA516371613B1/ar unknown
- 2016-08-04 MX MX2021006790A patent/MX2021006790A/es unknown
-
2018
- 2018-11-02 US US16/178,641 patent/US20190209478A1/en not_active Abandoned
-
2019
- 2019-03-04 JP JP2019038349A patent/JP6666490B2/ja active Active
- 2019-09-06 AU AU2019226239A patent/AU2019226239B2/en active Active
-
2020
- 2020-12-03 US US17/110,398 patent/US11925709B2/en active Active
-
2021
- 2021-10-08 AU AU2021245229A patent/AU2021245229A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/137,925 patent/US20230248655A1/en not_active Abandoned
- 2023-10-30 AU AU2023258317A patent/AU2023258317A1/en not_active Abandoned
-
2025
- 2025-08-22 AU AU2025220825A patent/AU2025220825A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006790A (es) | Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| EP4302830A3 (en) | Quinazoline derivatives used to treat hiv | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| MY192824A (en) | Compound targeting il-23a and tnf-alpha and uses thereof | |
| MX2017001379A (es) | Producto antiseptico, proceso para prepararlo y su uso. | |
| MY189913A (en) | Preparation containing tetracyclic compound at high dose | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| EP4620458A3 (en) | Ribociclib tablet | |
| EA201591397A1 (ru) | Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса | |
| PH12016501807A1 (en) | Novel compounds | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| NZ731344A (en) | Hydroxyl purine compounds and applications thereof | |
| TN2016000490A1 (en) | Naphthyridinedione derivatives. | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| PH12016502272A1 (en) | Ceritinib formulation | |
| MX371158B (es) | Compuestos inhibidores de pde2. |